How much revenue does ReNeuron Group make?

ReNeuron Group reported 530,000 GBP in revenue for fiscal year 2023, up 31.5% from 403,000 GBP in fiscal year 2022.

What companies are similar to ReNeuron Group?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Xeno Transplants Corporation (XENO), U.s. Stem Cell, Inc. (USRM), Amarantus BioScience Holdings, Inc. (AMBS), West Island Brands Inc. (WIBFF).

ReNeuron Group plc (RNUGF) Stock

About ReNeuron Group plc

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in ...

At a glance

ReNeuron Group reported revenue of 530,000 GBP for fiscal year 2023, up 31.5% from fiscal year 2022, and net income of -5.41 million GBP.

Figures from company filings; latest fiscal year ended March 31, 2023.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.